• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solana Company Reports First Quarter 2026 Financial Results

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026.

    First Quarter Recent Business Updates

    • Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yield
    • Executed approximately $3.5 million in share repurchases during the quarter under the Company's repurchase program
    • Advanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilities
    • Continued collaboration with Anchorage Digital and Kamino for institutional-grade staking and lending against natively staked SOL
    • Appointed Madelene Gani as Chief Operating Officer and Deputy Chief Financial Officer on April 6, 2026, bringing deep financial and operational expertise from hyper-growth Web3 companies

    "Despite the volatility in digital asset markets during the quarter, we remain focused on the fundamentals: growing our SOL per share through disciplined capital allocation, generating consistent staking yield, and building out the diversified revenue streams that we believe will drive long-term value creation," said Joseph Chee, Executive Chairman at Solana Company. "We are not simply holding digital assets; we are building an operating business with recurring revenue streams that leverage our institutional-grade infrastructure and our position as a strategic partner to the Solana Foundation."

    Cosmo Jiang, General Partner at Pantera Capital and board director at Solana Company said, "The first quarter demonstrated the resilience of our digital asset treasury strategy. Our average net staking yield reflects the institutional-grade infrastructure and active management approach that Pantera applies across its broader digital asset portfolio. We remain committed to capital allocation strategies that are accretive on a SOL per share basis."

    First Quarter 2026 Financial Results

    First quarter revenue was $3.6 million, consisting primarily of $3.4 million in staking rewards income and $0.2 million in other revenue. This represents significant growth from the $49,000 in revenue reported in the first quarter of 2025, which did not include staking revenue generated through the Company's digital asset treasury strategy.

    Cost of revenue for the first quarter was $0.2 million, resulting in a gross profit of $3.4 million compared to a gross loss of $72,000 in the prior-year period.

    General and administrative expenses for the first quarter of 2026 were $5.2 million, compared to $3.9 million in the first quarter of 2025, reflecting the expansion of operations associated with the Company's digital asset treasury strategy.

    Total operating expenses for the first quarter of 2026 were $103.1 million, compared to $3.9 million in the prior-year period. Operating expenses included non-cash charges of $89.2 million for unrealized loss on digital assets and digital assets receivable, $7.0 million for realized loss on digital assets related to strategic sales executed as part of the Company's capital allocation program, and $1.7 million for unrealized loss on digital assets fund investment.

    The resulting loss from operations was $99.6 million compared to a loss of $4.0 million for the prior-year period.

    Nonoperating expense for the quarter was $0.2 million, compared to nonoperating income of $0.2 million in the prior-year period.

    Reported net loss for the first quarter of 2026 was $99.8 million, or a loss of $1.30 per basic and diluted common share, compared to a net loss of $3.8 million, or a loss of $382.29 per basic and diluted common share, in the prior-year period.

    Cash and Liquidity

    At March 31, 2026, cash and cash equivalents totaled $4.4 million and digital assets and digital asset exposure at fair value totaled $193.8 million, including $21.0 million in current digital assets, $127.6 million in long-term digital assets, $23.6 million in restricted digital assets, $18.3 million in digital assets receivable, and $3.3 million in digital assets fund investment. Common shares issued totaled 56.6 million with 55.0 million outstanding as of March 31, 2026, net of treasury stock.

    Conference Call

    Management will host a conference call to discuss the results and provide an expanded business update as follows:

    Date:Friday, May 15, 2026
    Time:4:30 p.m. Eastern Time
    Webcast:Click here
    Participant call link:Click here (register to receive unique PIN and dial-in number)

      



    The webcast will be archived under the News & Events section of the Company's investor relations website. 

    About Solana Company

    Solana Company (NASDAQ:HSDT) is a listed digital asset treasury dedicated to acquiring SOL and focused on maximizing SOL per share by leveraging capital markets opportunities and on-chain activity, Solana Company offers public market investors optimal exposure to Solana's secular growth. https://www.solanacompany.co/

    Forward Looking Statements

    This press release contains statements that constitute "forward-looking statements" within the meaning of the U.S. federal securities laws. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms or other comparable terminology. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Forward-looking statements may include, among others, statements in relation to the expected benefits and implementation of the Company's digital asset treasury strategy and the Company's future growth and operational progress.

    These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors-many of which are beyond the Company's control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, capital requirements to achieve the Company's business objectives; expected benefits and implementation of the Company's digital asset treasury strategy, expected staking, yield and broader opportunities across the Solana ecosystem; the Company's expected token treasury growth, the impact on the Company of global macroeconomic conditions including risks related to logistics challenges, labor shortages, disruptions in the banking system and financial markets; high levels of inflation and high interest rates on the Company's ability to operate its business and access capital markets; the success of the Company's business plan; the Company's operating costs and use of cash; the Company's ability to achieve significant revenues; and other risks and uncertainties described under "Risk Factors" in the  Company's Annual Report on Form 10-K for the year ended December 31, 2025, and in other subsequent filings with the SEC, including its upcoming Quarterly Report on Form 10-Q for the quarter ended March 31, 2026,. These filings are available at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

    Media Contacts:

    Solana Company

    ir@solanacompany.co

          
          
    Solana Company

    Unaudited Condensed Consolidated Balance Sheets

    (in thousands, except share data)

          
     March 31, 2026    December 31, 2025
    ASSETS       
    Current assets       
    Cash and cash equivalents$4,395  $7,282 
    Digital assets 21,000   21,000 
    Prepaid expenses and other current assets 2,443   2,873 
    Total current assets 27,838   31,155 
    Digital assets 127,587   196,724 
    Digital intangible assets, restricted 23,564   39,219 
    Digital assets receivable 18,347   31,139 
    Digital assets fund investment 3,304   5,617 
    Other long-term assets 68   75 
    Total assets$200,708  $303,929 
    LIABILITIES AND STOCKHOLDERS' EQUITY       
    Current liabilities       
    Accounts payable$2,003  $1,890 
    Accrued and other current liabilities 808   1,126 
    Total current liabilities 2,811   3,016 
    Stockholders' equity       
    Class A common stock, $0.001 par value; 800,000,000 shares authorized; 56,565,079 shares issued and 54,961,108 outstanding and 43,744,207 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 57   44 
    Additional paid-in capital 513,796   513,719 
    Accumulated deficit (312,388)  (212,589)
    Accumulated other comprehensive loss (44)  (261)
    Treasury stock, at cost (3,524)  — 
    Total stockholders' equity 197,897   300,913 
    Total liabilities and stockholders' equity$200,708  $303,929 



          
    Solana Company

    Unaudited Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

          
     Three Months Ended
     March 31, 
     2026

     2025

    Revenue          
    Staking revenue$3,417  $— 
    Other revenue 204   49 
    Total revenue 3,621   49 
    Cost of revenue 180   121 
    Gross profit (loss) 3,441   (72)
    Operating expenses     
    General and administrative expenses 5,189   3,939 
    Unrealized loss on digital assets and digital assets receivable 89,198   — 
    Realized loss on digital assets 6,987   — 
    Unrealized loss on digital assets fund investment 1,685   — 
    Total operating expenses 103,059   3,939 
    Loss from operations (99,618)  (4,011)
    Nonoperating income     
    Change in fair value of derivative liability —   109 
    Other (expense) income (181)  64 
    Nonoperating income, net (181)  173 
    Loss before provision for income taxes (99,799)  (3,838)
    Provision for income taxes —   — 
    Net income (loss)$(99,799) $(3,838)
    Earnings (loss) per share     
    Basic and diluted$(1.30) $(382.29)
    Weighted average number of common shares outstanding     
    Basic and diluted 76,736,156   10,039 
            


    Primary Logo

    Get the next $HSDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    4/23/2026$3.00Buy
    B. Riley Securities
    4/6/2026$4.00Buy
    Maxim Group
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    SEC Filings

    View All

    Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Solana Co (0001610853) (Filer)

    5/29/26 5:16:57 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Solana Company

    424B5 - Solana Co (0001610853) (Filer)

    5/29/26 5:08:05 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SD filed by Solana Company

    SD - Solana Co (0001610853) (Filer)

    5/29/26 4:05:58 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    6/4/26 8:12:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Jiang Cosmo Yi

    4 - Solana Co (0001610853) (Issuer)

    6/4/26 8:10:56 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)

    4 - Solana Co (0001610853) (Issuer)

    5/26/26 7:30:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company Reports First Quarter 2026 Financial Results

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yieldExecuted approximately $3.5 million in share repurchases during the quarter under the Company's repurchase programAdvanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilitiesContinued collaboration wit

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026

    NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced that the Company will release its first quarter operating results on Friday, May 15 2026, after market close. Management will host a conference call to discuss the results and provide a business update as follows: Date:Friday, May 15, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Company Solana Company (NASDAQ:HSDT) is a listed digital a

    5/11/26 4:16:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region

    MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- Jito Foundation, the organization supporting the development of the Jito ecosystem and the team behind the execution infrastructure underpinning the Solana network, today announced a strategic partnership with Solana Company (NASDAQ:HSDT), a leading institutional blockchain infrastructure company for the Solana ecosystem. The partnership is intended to focus on building institutional-grade validator infrastructure, advancing yield optimization, and accelerating institutional adoption of Solana across the APAC region.  Bringing Solana's market layer infrastructure into APAC's financial hubsThrough the collaboration, Solana Company and the Jito Founda

    5/6/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Solana Company with a new price target

    B. Riley Securities initiated coverage of Solana Company with a rating of Buy and set a new price target of $3.00

    4/23/26 8:09:25 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Maxim Group resumed coverage on Solana Company with a new price target

    Maxim Group resumed coverage of Solana Company with a rating of Buy and set a new price target of $4.00

    4/6/26 8:28:30 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth

    Gani is a proven transformation leader with track record at Hedera Hashgraph, Aptos, Gemini Space Station, and JUUL Labs. She joins to accelerate Solana Company's next phase of growth.Gani brings deep financial and operational expertise in public companies, global financial infrastructure buildout, and operational scaling that has driven hundreds of millions in value creation across hyper-growth companies.Strategic hire signals Solana Company's commitment to institutional-grade operations as it expands its digital asset treasury and infrastructure globally. NEWTOWN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) today announced the appointment of Madelene Gani, CPA,

    4/9/26 4:15:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports First Quarter 2026 Financial Results

    NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily driven by the Company's SOL earning staking yieldExecuted approximately $3.5 million in share repurchases during the quarter under the Company's repurchase programAdvanced the Pacific Backbone validator infrastructure initiative through strategic partnership with Jito to accelerate staking infrastructure development and MEV capture capabilitiesContinued collaboration wit

    5/15/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026

    NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company, today announced that the Company will release its first quarter operating results on Friday, May 15 2026, after market close. Management will host a conference call to discuss the results and provide a business update as follows: Date:Friday, May 15, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived under the News & Events section of the Company's investor relations website.  About Solana Company Solana Company (NASDAQ:HSDT) is a listed digital a

    5/11/26 4:16:12 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care